The Ethical Review of Health Care Quality Improvement Initiatives: Findings From the Field by Holly A. Taylor et al.
Issue Brief
August 2010
The Ethical Review of Health Care 
Quality Improvement Initiatives: 
Findings from the Field
Holly A. TAylor, PeTer J. PronovosT, ruTH r. FAden, 
nAncy e. KAss, And Jeremy sugArmAn 
JoHns HoPKins universiTy
ABSTRACT: Questions have been raised about whether and how health care quality 
improvement (QI) initiatives ought to be reviewed to address possible ethical issues asso-
ciated with them. These questions have focused primarily on whether some QI initiatives 
meet the regulatory criteria for human subject research and should therefore be regulated 
and reviewed as such. Based on surveys of health care system professionals conducting QI 
initiatives and hospital CEOs, the authors find that QI initiatives are routinely reviewed 
by a variety of internal mechanisms prior to implementation, although rarely through an 
institutional review board or another independent body charged specifically with ethical 
oversight of QI initiatives. Further research, the authors say, is needed to achieve a bet-
ter understanding of how review mechanisms for QI initiatives are structured, including 
information on who reviews these activities, how they are reviewed, and whether such 
processes include an ethical assessment of the proposed QI initiative.
                    
OvERvIEw
Over the last two decades, quality improvement (QI) initiatives have burgeoned 
in hospitals and health care systems.1 While enhancing the quality of health care 
is important and often required by accrediting organizations and others, the pro-
cess of improvement can raise ethical issues. Perhaps not surprisingly, there has 
been occasional, yet intensive, professional and public scrutiny regarding the ethi-
cal oversight of QI initiatives.
For instance, in 2001, questions were raised about a project on end-stage 
renal disease funded by the Centers for Medicaid and Medicare Services (CMS). 
Although CMS considered it to be a QI initiative, the Office for Human Research 
Protection (OHRP) determined the project was human subject research and that 
it should have been reviewed as such by an IRB prior to its implementation.2 In 
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2007, an anonymous whistle-blower accused the lead-
ers of a project funded by the Agency for Healthcare 
Research and Quality (AHRQ) to reduce life-threat-
ening infections in intensive care units of not having 
received proper ethical review.3 That project involved 
testing the effectiveness of a checklist for improving 
the safety of intravenous catheters across hospitals 
in Michigan. The primary questions raised related to 
ethics oversight were whether the project constituted 
research and needed to be reviewed by institutional 
review boards (IRBs) at all participating hospitals, and 
whether informed consent should have been obtained 
from all patients who were involved.4
As noted by many commentators, QI and 
patient safety can be stymied unless there is a coher-
ent approach to the ethical oversight of QI initiatives. 
However, achieving this turns out to be surprisingly 
complicated.
In the early 1990s, questions began to be raised 
as to whether quality improvement initiatives ought to 
be considered human subject research and reviewed 
and regulated as such.5 Since then, a number of pro-
posals have suggested criteria by which QI initiatives 
might be distinguished from human subject research, 
assuming that the latter requires review by an IRB 
while the former does not.6 Other proposals attempted 
to examine whether formal ethical oversight of these 
activities is needed by focusing on the risk to potential 
participants posed by such activities, or the ways in 
which such activities potentially veer from the inter-
ests of current patients.7 The goals of these proposals 
were to: 1) address, among other things, QI practitio-
ners’ uncertainty as to whether their activities should 
be reviewed by IRBs; and 2) limit the volume of QI 
initiatives unnecessarily referred to IRBs already bur-
dened with a heavy volume of human subject research 
(Exhibit 1).
While there is no consensus regarding the cor-
rect approach, there is an obvious need for oversight of 
at least some QI initiatives. In addition, many propos-
als rest upon the current system of ethical oversight 
of research, although others suggest the possibility of 
developing and using other approaches.
Despite myriad proposals regarding the ethical 
oversight of QI, there is surprisingly little empirical 
research that has reported on the review and oversight 
of QI initiatives. One group of investigators surveyed 
IRBs at academic medical centers to find out whether 
they had local guidelines regarding the review and reg-
ulation of QI initiatives.8 They found that the variety 
of attributes used by IRBs to distinguish QI initiatives 
from human subject research mirrored those found 
in the literature. A second group of investigators sur-
veyed IRB chairs and quality officers at hospitals with 
at least 400 beds; they also surveyed editors of peer-
reviewed journals.9 In response to a set of six vignettes 
about hypothetical projects, they found quality officers 
less likely than either IRB chairs or journal editors to 
respond that a project needed to be reviewed by an 
IRB, and found disagreement between quality officers 
and IRB chairs from the same institution.
In this issue brief, we describe our recent efforts 
to collect data to advance the policy debate.
EmpIRICAl DATA FROm HEAlTH CARE 
pROFESSIOnAlS AnD SySTEmS
To inform the development of policy regarding the 
appropriate ethical oversight for QI research activities, 
we surveyed two groups: health care system profes-
sionals conducting QI initiatives, and the leadership 
of those organizations in which QI activities are con-
ducted. Our first survey, conducted in collaboration 
with the Institute for Healthcare Improvement (IHI), 
was completed in April 2009.10 The second survey was 
conducted in November and December of 2009 with 
CEO members of the American Hospital Association 
(AHA). Both surveys are described briefly in turn, fol-
lowed by a comparison of the results. These studies 
begin to fill a gap in whether institutions have viewed 
their QI work as research and what types of ethical 
oversight such projects have received.
Survey of QI practitioners 
Our first survey was of quality improvement practi-
tioners (QIPs) who had participated in the Institute for 
Healthcare Improvement’s “100,000 Lives” Campaign, 
which recruited hospitals and health systems to adopt 
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patient-safety initiatives aimed at reducing medical 
harm.11 The survey was sent to 500 QIPs, and 126 
(25%) responded.
QI review mechanisms. The majority of IHI respon-
dents in this study self-identified as managers either 
in a QI/safety department or other hospital department 
(n=63). Most respondents indicated that QI initiatives 
conducted by faculty and staff affiliated with their 
organization are subject to some type of review prior to 
implementation (83%); of those, most reported that the 
review is conducted most of the time or always (85%). 
The three most common mechanisms reported were 
review by: the QI management team/office; clinical 
leadership conducting QI; and an advisory board (or 
equivalent) created for the purpose of reviewing QI. 
Two-thirds of respondents indicated that the QI over-
sight mechanism in place at their institution identifies 
and considers ethical issues related to QI well or very 
well. A minority of respondents (20%) indicated that 
the national policy discussions about the oversight of 
QI affected ongoing or planned QI projects in which 
they were involved.
Ethical considerations. Respondents were given a set 
of considerations thought to be relevant to the ethical 
conduct of QI initiatives. They were asked to indicate: 
1) whether each was relevant to the ethical conduct of 
QI initiatives at their institution; and 2) how impor-
tant they believed each such consideration was for the 
ethical conduct of QI generally. Eighty-three percent 
and 82 percent of respondents, respectively, strongly 
Exhibit 1. Proposed Criteria
Criteria Reference(s)
Characterization of benefits is contested Lo and Groman 2003
Delayed or ineffective feedback of results to subjects of project Lynn 2004; Baily, Bottrell, Jennings et al. 2006; Lynn et al. 2007
Engagement with/commitment to the local setting Brett and Grodin 1991; Lynn 2004; Baily, Bottrell, Jennings et al. 2006; Lynn et al. 2007
Intent/goal of the initiator Brett and Grodin 1991; Wagner 2003
Intent to publish 
Koshcnitzke, McCracken and Pranulis 1992
(Note: Casarett, Karlawish and Sugarman 2000; Lo and Groman 
2003 disagree that intent to publish ought to serve as criteria to 
distinguish quality improvement initiatives from human subject 
research.)
Majority of patients are not expected to benefit directly from the 
knowledge to be gained Casarett, Karlawish and Sugarman 2000
Novelty of intervention Brett and Grodin 1991; NBAC 2001; Lo and Groman 2003; Baily, Bottrell, Jennings et al. 2006; Lynn et al. 2007
Majority of patients are expected to benefit directly from the 
knowledge to be gained but they would be subjected to additional 
risks or burdens beyond usual clinical practice to make the results 
generalizable.
Casarett, Karlawish and Sugarman 2000
Patients to be exposed to more than minimal risk. For example, 
patients to receive less care that is considered standard. Lo and Groman 2003; Goldman et al. 2010; Lynn 2004
Prospective design Brett and Grodin 1991; Koshcnitzke, McCracken and Pranulis 1992; Bellin and Dubler 2001
Utilizes methods and techniques commonly used in research  
(e.g., randomization)
Wagner 2003; Lynn 2004; Baily, Bottrell, Jennings et al. 2006; Lynn 
et al. 2007
Substantial funding, funding from an outside organization Lynn 2004; Baily, Bottrell, Jennings et al. 2006; Lynn et al. 2007
Substantial nontherapeutic aims; aims of project extend beyond the 
immediate interests of patients subject to the activity. Lynn 2004; Grady 2007
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agreed that minimal risk to patients and privacy and 
confidentiality are guiding principles for QI initiatives 
conducted at their institution and to QI more generally. 
A majority of respondents also agreed that assessing 
established practices (67%), scientifically sound design 
(62%), transparency (62%), and the identification and 
minimization of potential conflicts (57%) are ethical 
considerations for QI initiatives conducted at their 
institution.
Survey of Hospital CEOs
Our second survey, conducted in collaboration with the 
American Hospital Association, was designed to get 
perspective on the results from the previous survey of 
CEOs at U.S. hospitals and health systems. The survey 
was limited to five questions, and we asked the most 
informative items from the first survey. The methods 
used for the AHA survey were similar to those used in 
the first survey.
The survey was sent to 5,807 potential respon-
dents by e-mail or fax (depending on the respondents’ 
previously stated preference) on November 30, 2009. 
A notice about the survey distribution and request 
for completion was posted in the weekly newslet-
ter sent to AHA members. Eligible respondents were 
sent a reminder and a second request for completion 
was posted in the AHA newsletter. We also abstracted 
demographic data regarding hospitals and health 
systems represented in the AHA database including 
region, teaching hospital or not, and number of hospital 
Exhibit 2. AHA Sample—Regional Diversity
Census Division/Region
Survey Sample 
(n=297)
Total AHA Sample 
(n=5,807)
Puerto Rico (0) 0 (0%) 60 (1%)
New England/Northeast (1) 17 (6%) 230 (4%)
Mid-Atlantic/Northeast (2) 27 (9%) 522 (14%)
East North Central/Midwest (3) 40 (14%) 833 (14%)
West North Central/Midwest (4) 57 (19%) 858 (15%)
South Atlantic/South (5) 20 (7%) 497 (9%)
East South Central/South (6) 53 (18%) 743 (12%)
West South Central/South (7) 40 (13%) 1,023 (18%)
Mountain/West (8) 20 (7%) 440 (8%)
Pacific/West (9) 23 (7%) 601 (10%)
Exhibit 3. AHA Sample—Number of Beds
Number of Beds
Survey Sample
(n=297)
Total AHA Sample
(n=5,807)
1–24 29 (10%) 609 (10%)
25–49 63 (21%) 1,347 (23%)
50–99 65 (22%) 1,196 (21%)
100–199 50 (17%) 1,201 (21%)
200–299 34 (11%) 628 (11%)
300–399 23 (7%) 367 (6%)
400–499 11 (4%) 187 (3%)
500+ 22 (7%) 272 (5%)
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beds. The statistical analysis was descriptive, using 
means and medians as appropriate. To identify asso-
ciations between survey questions and demographic 
data, we used logistic regression models. A total of 297 
respondents completed the survey (response rate=5%). 
(No trends were found that indicated that our sample 
AHA respondents diverged substantively from the 
AHA population; see Exhibits 2 and 3.)
Frequency of review. Seventy-one percent of AHA 
CEO respondents indicated that QI initiatives con-
ducted by faculty and staff affiliated with their organi-
zation always are reviewed by some entity within their 
organization prior to implementation, while 26 percent 
stated that QI initiatives sometimes were reviewed 
prior to implementation (Exhibit 4).
Type of oversight mechanism. Only one-quarter (23%) 
of AHA CEO respondents indicated that initiatives 
were routinely submitted to their IRB. No statistical 
relationship was found between the AHA respon-
dent’s stated affiliation with a teaching hospital and a 
report of routinely submitting QI initiatives to an IRB 
(Exhibit 5).
Source of funding for QI efforts. When asked how QI 
initiatives were funded at their institution, AHA CEOs 
most commonly cited internal organizational fund-
ing. A statistically significant relationship was found 
between the respondent’s relationship to a teaching 
hospital and the receipt of federal funding to conduct 
QI initiatives (p=.02) (Exhibit 6).
Exhibit 4. AHA Survey—Frequency of QI Review
Frequency of QI Review Number Percentage
Always 211 71%
Sometimes 77 26%
Seldom 7 2%
Never 0 0%
Don’t know 2 1%
Total 297 100%
Exhibit 5. AHA Survey—Type of Oversight Mechanism
Mechanism Yes No Don’t Know
Advisory/managerial board (or equivalent) not created specifically 
for the purpose of reviewing QI initiatives 156 (57%) 115 (42%) 3 (1%)
Advisory/managerial board (or equivalent) created specifically for 
the purpose of reviewing QI initiatives 176 (64%) 99 (36%) 2 (1%)
QI management team/office 268 (93%) 21 (7%) 0 (0%)
Oversight by a standing clinical/medical leadership team 226 (81%) 53 (19%) 0 (0%)
Clinical leaders conducting QI initiatives 240 (86%) 36 (13%) 3 (1%)
Local institutional policy specific to QI initiatives 140 (53%) 111 (42%) 12 (5%)
Routine submission of QI initiatives to an IRB 58 (23%) 179 (72%) 13 (5%)
Note: Respondents marked all that were applicable.
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Consideration of ethical issues. More than three-
quarters of AHA CEO respondents indicated that the 
oversight mechanism in place at their institution does 
“well” (56%) or “very well” (26%) identifying and 
considering ethical issues related to the QI initiatives 
submitted for review. No statistically significant rela-
tionship was found between respondents reporting 
how well the oversight mechanism reviews the ethical 
issues related to their QI initiative with routine submis-
sion to an IRB (Exhibit 7).
Guiding ethical considerations for QI. The major-
ity of AHA CEO respondents ranked minimal risk to 
patients/health care providers/systems, assessing estab-
lished practices (initiating a practice seen to be safe 
and effective in other settings, or combining changes in 
practice all found to be safe and effective but not previ-
ously adopted as a package), and attention to privacy 
and confidentiality (upholding professional standards 
and HIPAA compliance) as the ethical considerations 
that ought to guide the QI initiatives conducted at their 
institutions (Exhibit 8).
Comparing the Results
Given such a low response rate to the survey of AHA 
CEOs, we believe the results from the IHI QIP survey 
are more reliable. However, the results of the AHA 
survey seem to corroborate the findings from the IHI 
survey. Following are some noteworthy comparisons 
among the results:
Compared with the IHI QIPs surveyed, many •	
more AHA CEOs reported that QI initiatives are 
always reviewed (70%). Of the IHI QIP respon-
dents who indicated QI initiatives are subject 
to review, 33 percent reported that a review is 
always conducted and 50 percent that a review 
is conducted sometimes.
A similar minority of IHI QIP and AHA CEO •	
respondents reported sending QI initiatives to an 
IRB for review.
Nearly twice as many AHA CEOs as IHI QIPs •	
indicated that QI initiatives at their institu-
tion are funded by internal sources (IHI=40%; 
AHA=70%).
A larger proportion of AHA CEO respondents •	
reported that the oversight mechanism pays 
attention to ethical issues “well” (IHI=45%; 
AHA=56%).
Comparing the AHA CEO respondent ranking •	
and the IHI QIP respondent ranking of the top 
four ethical considerations that ought to guide 
the QI initiatives conducted at their institutions, 
the only difference was that AHA CEO respon-
dents ranked assessing established practices 
second on their list, while IHI QIP respondents 
ranked it third.
Exhibit 6. AHA Survey—Funding Source for QI Initiatives
Funding Source Number/(Percentage) Reporting Yes
Internal organizational funding 190 (70%)
State funding 66 (24%)
Foundation grant 52 (19%)
Federal funding 45 (15%)
Pharmaceutical industry 8 (3%)
Other private industry funding 10 (4%)
None 6 (2%)
Other 11 (4%)
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Toward Best practices for  
QI Ethical Review
Further research is needed for a better understanding of 
how existing review mechanisms for QI initiatives are 
structured, including who reviews these activities, how 
they are reviewed, and whether such processes include 
an ethical assessment of the proposed QI intervention. 
Simply put, whether and to what extent the review 
attends to the ethics of the initiative remains unknown. 
Little is known also about the training, skills, or pro-
cess used for the non-IRB reviews, although there is 
likelihood of wide variation. And little is known about 
how IRBs approach QI initiatives, the consequent mod-
ifications of QI activities (such as a change in design 
or requiring informed consent), and the implications of 
reviewing QI on IRBs.
With further investigation, sound practices 
with regard to the ethical review of QI initiatives 
might well be identified. Such research could identify 
important insights that could lead to the development 
of best practices, including the relative importance of 
DISCuSSIOn
According to our data, quality improvement initiatives 
are routinely reviewed by a variety of internal mecha-
nisms prior to implementation, although rarely through 
the institutional review board or any other independent 
body charged specifically with ethical oversight. In 
fact, only a few respondents indicated that they submit 
QI initiatives to an IRB. While questions have been 
raised about the independence of IRBs, one could 
argue that the IRB could provide a more independent 
assessment of QI initiatives than could offices and 
individuals who are administratively responsible for 
QI efforts or otherwise closely connected with them.12 
However, this concern begs the question of whether 
the IRB is properly constructed to conduct reviews of 
QI. As argued by Perneger, a central issue seems to be 
independent ethical review.13 Also relevant is whether 
activities which pose little if any risks or burdens even 
require such a review.
Exhibit 7. AHA Survey—Consideration of Ethical Issues
Consideration of Ethical Issues Number Percentage
Very well 76 26%
Well 166 56%
Not well 32 11%
Don’t know 23 8%
Total 297 100%
Exhibit 8. AHA Survey—Ethical Considerations
RANKING
Consideration 1 2 3 Total
Minimal risk to patients 140 43 22 205 (70%)
Assessing established practices 52 56 62 170 (57%)
Privacy and confidentiality 39 74 52 165 (55%)
Transparency 16 42 54 113 (38%)
Balancing 16 24 28 69 (23%)
Scientifically sound design 16 27 23 67 (23%)
Commitment to shared learning 5 17 31 54 (19%)
Identification and minimization of conflicts of interest 1 2 13 17 (6%)
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the ethical issues identified by both the IHI and AHA 
respondents as those most relevant to the conduct of QI.
The respondents to our surveys agree that the 
ethical considerations most relevant to the conduct of 
QI are: exposing those subjected to the QI initiative 
(i.e., patients, health care providers, systems) to no 
more than minimal risk, the assessment of established 
practices, and respect for the privacy and confidential-
ity of those subject to the QI initiative. While these 
data are important, attitudes about ethical issues are 
not normative, and a robust moral framework for the 
systematic integration of QI research and practice with 
health care delivery is needed.
The key question going forward is not how to 
distinguish QI from research; advances in QI require 
the conduct of QI research. Rather, the challenge 
rests in constructing a system that provides incentives 
for the development, evaluation, dissemination, and 
implementation of effective interventions to improve 
the quality and safety of medical care (ends shared 
by all participants in the health care system), while 
at the same time providing appropriate safeguards 
for patients and clinicians affected by the activities—
whether deemed research or not.
In conclusion, the characteristics of QI initia-
tives deemed to require IRB review have evolved over 
time, yet there is still a lack of consensus on this issue. 
Similarly, there remains little consensus regarding 
the characteristics that distinguish QI initiatives from 
human subjects research. Pursuing such paths may 
ultimately not prove to be the most useful approach to 
determine the appropriate mechanism, or mechanisms, 
for the ethical oversight of QI. Our research suggests 
that the review of QI initiatives varies widely among 
hospitals, though most are not reviewed by an IRB. 
Further research is needed to understand barriers to the 
review of QI, the efficacy of alternative approaches to 
review, and the development and dissemination of best 
practices regarding review of QI studies. This research 
is essential to ensuring that we continue to improve 
quality of care and protect patients’ rights and interests.
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